Archives
-
LRG1, Neutrophil NETosis, and Bladder Cancer
2026-09-11
A 2026 Advanced Science study identifies a tumor-derived LRG1–ANXA2 pathway that disrupts neutrophil mitochondrial homeostasis, promotes NETosis, and destabilizes bladder cancer vasculature. Its integrated single-cell, biochemical, animal-model, and clinical analyses suggest that blocking this axis may improve vascular normalization, drug delivery, T-cell infiltration, and responses to cisplatin or anti-PD-1 therapy.
-
Palbociclib (PD0332991) Assay Workflows
2026-09-11
Build reproducible CDK4/6 experiments around Rb phosphorylation, cell-cycle profiling, and apoptosis rather than viability alone. This workflow also shows how Palbociclib can complement genotype-aware DNA-repair studies without overstating what the reference evidence proves.
-
Ajugol, Mitophagy, and Gouty Arthritis Pyroptosis
2026-09-10
The reference study identifies impaired PINK1/Parkin-dependent mitophagy as a mechanistic link between PI3K/AKT/mTOR signaling, mitochondrial stress, and chondrocyte pyroptosis in acute gouty arthritis. By combining computational analysis with cell and mouse experiments, it shows that ajugol protects cartilage partly by suppressing this pathway and restoring mitochondrial quality control.
-
STL427944 Targets FOXM1 to Overcome Chemoresistance
2026-09-10
The reference study identified STL427944 through gene network analysis and showed that it suppresses FOXM1 by relocating the protein from the nucleus to the cytoplasm, followed by autophagic degradation. This mechanism sensitized human cancer cells to platinum agents, 5-fluorouracil, and taxanes, providing a mechanistic framework for studying FOXM1-driven treatment resistance.
-
BAPTA: A Causal Tool for Calcium Signaling
2026-09-09
BAPTA is a high-affinity calcium chelator for dissecting intracellular Ca2+ control, not merely a generic apoptosis reagent. This article translates nanoplastic–cadmium findings into a rigorous assay strategy for calcium signaling modulation, causal inference, and reproducible cell signaling studies.
-
ARCA Cy5 EGFP mRNA (5-moUTP) Workflow
2026-09-09
Use one reporter to distinguish mRNA uptake from productive translation in mammalian cells. ARCA capping, 5-methoxyuridine modification, Cy5 labeling, and EGFP expression make this reagent useful for delivery benchmarking, localization studies, and formulation stress testing.
-
Everolimus Workflows for mTOR Cancer Assays
2026-09-08
Build more informative RAD001 experiments by separating growth arrest from cell killing instead of treating one viability value as a complete drug response. This workflow combines mTOR pharmacodynamic markers, time-resolved viability, and apoptosis assays for more defensible cancer-model comparisons.
-
GLT-1, CB1-CREB Signaling, and TBI Recovery
2026-09-08
A 2025 Biomolecules study identifies astrocytic GLT-1 loss as an early contributor to glutamate excitotoxicity, neuronal apoptosis, and cognitive dysfunction after traumatic brain injury. Its experiments connect elevated 2-arachidonoylglycerol to CB1-dependent suppression of CREB phosphorylation and GLT-1 expression, providing a mechanistic framework for interpreting endocannabinoid interventions in TBI.
-
Substance P: From Mechanism to Translational Signal
2026-09-07
A thought-leadership guide to using Substance P as a mechanistic probe in pain transmission research, neuroinflammation, and immune response modulation, with practical handling guidance and an analytical framework inspired by fluorescence-based bioaerosol classification.
-
RapaLink-1: Translating mTOR Inhibition Across Models
2026-09-07
RapaLink-1 offers a mechanistically differentiated approach to mTOR inhibition by bridging binding sites associated with earlier inhibitor generations. This thought-leadership analysis connects its resistance-focused cancer biology with emerging mTOR-based dormancy models while separating established evidence from translational hypotheses.
-
VE-822 ATR Inhibitor: Radiosensitization Workflows
2026-09-05
VE-822 is a potent ATR inhibitor for testing replication-stress vulnerabilities, radiation response, and gemcitabine combinations in 2D and 3D cancer models. This practical guide translates comparative radiosensitizer data into assay design, formulation, dose scheduling, and troubleshooting strategies for PDAC and broader cancer research.
-
RapaLink-1 for mTORC1 and Dormancy Assays
2026-09-04
RapaLink-1 is a third-generation mTOR inhibitor for probing resistant mTOR signaling in glioma models and pharmacologically induced embryonic dormancy. This practical guide connects validated cancer workflows with cautious, evidence-based assay extensions for embryos, blastoids, and pluripotent stem cells.
-
Clarithromycin: Reliable CYP3A Assay Design
2026-09-04
Learn how Clarithromycin (SKU A4322) can support controlled CYP3A inhibition, drug-drug interaction research, and interpretation of cell viability or proliferation assays. This scenario-based guide covers stock preparation, exposure design, assay controls, data interpretation, and practical product selection.
-
Cy3 Goat Anti-Human IgG Antibody Guide
2026-09-03
The Cy3 Goat Anti-Human IgG (H+L) Antibody is a Cy3 conjugated secondary antibody for fluorescence-based detection of human IgG in immunofluorescence assay, immunohistochemistry, flow cytometry, and ELISA workflows. Its defined spectral peaks, liquid formulation, and affinity purification support sensitive indirect detection when storage and assay compatibility are controlled.
-
Allosteric PDK4 Inhibitors for Metabolic Disease
2026-09-03
The 2019 Journal of Medicinal Chemistry study used anthraquinone-based structural optimization to identify compound 8c, an allosteric PDK4 inhibitor with 84 nM in vitro potency and activity in metabolic, allergic, and cancer-related models. Its combination of biochemical potency, favorable preliminary disposition, docking support, and mouse efficacy illustrates how PDK4-directed PDH activation may be investigated while remaining firmly preclinical.